Sumitomo Pharma Co., Ltd.
4506
Rank in Stocks
#3233
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Share Price
$12.28
Market Cap
$5.51B
Change (1 day)
0.59%
Change (1 year)
8.21%
Country
JP
Trade Sumitomo Pharma Co., Ltd. (4506)
Category
Healthcare
P/E ratio for Sumitomo Pharma Co., Ltd. (4506)
P/E ratio as of October 2026 TTM: 6.54
According to Sumitomo Pharma Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 6.54. At the end of 2024 the company had a P/E ratio of -0.51.
P/E ratio history for Sumitomo Pharma Co., Ltd. from 2005 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 6.54 | -46.61% |
| 2025 | 12.25 | -2,493.01% |
| 2024 | -0.51 | -88.14% |
| 2023 | -4.32 | -150.77% |
| 2022 | 8.51 | -37.53% |
| 2021 | 13.62 | -0.44% |
| 2020 | 13.68 | -39.08% |
| 2019 | 22.45 | 69.12% |
| 2018 | 13.28 | -47.29% |
| 2017 | 25.19 | 20.81% |
| 2016 | 20.85 | -43.08% |
| 2015 | 36.63 | 12.76% |
| 2014 | 32.48 | -50.45% |
| 2013 | 65.55 | 62.34% |
| 2012 | 40.38 | 120.26% |
| 2011 | 18.33 | 12.84% |
| 2010 | 16.25 | -0.10% |
| 2009 | 16.26 | 14.94% |
| 2008 | 14.15 | -36.09% |
| 2007 | 22.14 | -7.23% |
| 2006 | 23.87 | -3.68% |
| 2005 | 24.78 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 434.51% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.